Back to Journals » OncoTargets and Therapy » Volume 11

Prognostic value of NEK2 overexpression in digestive system cancers: a meta-analysis and systematic review

Authors Ren Q, Li B, Liu M, Hu Z, Wang Y

Received 2 April 2018

Accepted for publication 5 July 2018

Published 18 October 2018 Volume 2018:11 Pages 7169—7178

DOI https://doi.org/10.2147/OTT.S169911

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Cho


Qian Ren,1,2 Bowen Li,3 Min Liu,1,2 Zenan Hu,1,2 Yuping Wang1,2

1Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, People’s Republic of China; 2Key Laboratory for Gastrointestinal Diseases of Gansu Province, Lanzhou University, Lanzhou, People’s Republic of China; 3Department of Pediatrics, The First Hospital of Lanzhou University, Lanzhou, People’s Republic of China

Background and objective: Many studies have reported that NEK2 is overexpressed in digestive system cancers (DSCs) and is also correlated with patient survival. We performed a meta-analysis to comprehensively evaluate the prognostic role of NEK2 expression in DSCs.
Materials and methods: A comprehensive literature search was performed using PubMed, EMBASE, and Web of Science. Synthesized hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the influence of NEK2 overexpression on the prognosis and clinicopathological features of patients with DSCs.
Results: A total of 13 studies involving 1,917 patients was included. Overall, patients with high NEK2 expression had poorer overall survival (HR =1.45; 95% CI: 1.15–1.83; P=0.002) and disease-free survival/recurrence-free survival (HR =2.28; 95% CI: 1.54–3.37; P<0.0001). Furthermore, subgroup analysis also suggested that elevated NEK2 expression was associated with poorer overall survival in patients with hepatocellular carcinoma (HR =1.45; 95% CI: 1.05–2.00; P=0.02) and colorectal cancer (HR =2.03; 95% CI: 1.16–3.54; P=0.01). Additionally, NEK2 overexpression was also associated with pretreatment serum AFP level (OR =1.79; 95% CI: 1.23–2.61; P<0.01) and portal vein thrombosis (OR =2.74; 95% CI: 1.22–6.17; P=0.01) in hepatocellular carcinoma.
Conclusion: NEK2 might act as a useful prognostic predictor and a potential therapeutic target in DSCs. However, multicenter homogeneous studies with larger sample sizes are needed to further confirm our findings owing to some limitations in our meta-analysis.

Keywords: NEK2, digestive system cancer, prognostic, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]